Cell Impedance as a Tool to Measure Potency of Chimeric Antigen Receptor T cells
Cell-based immunotherapy using chimeric antigen receptor T cells (CarT) has shown promise as a next-generation treatment for cancer. With the rapid growth of this novel immunotherapy comes the challenge of accurately measuring the efficacy of a highly individualized “living drug”.
Watch the webinar on demand to learn about:
- A multi-platform approach developed at Tmunity Therapeutics to build an innovative “toolbox” of orthogonal assays used to provide a comprehensive set of data to characterize T cell-based therapeutic products.
- How the measurement of cell impedance in co-culture assays using CAR-T cells offers several advantages over traditional cytotoxicity assays and thereby providing a more robust assessment of drug product potency
About the Speaker:
Dr. Daniel Hui is currently a member of the Analytical Development group at Tmunity Therapeutics, developing innovative new tools and methods to study T cell function. Dr. Hui earned his Bachelor of Science degree in microbiology from the University of Pittsburgh. He attended graduate school at Case Western Reserve University and received his doctoral training in the lab of Ganes Sen, Ph.D. at the Cleveland Clinic Foundation, studying the innate immune system and interferon signaling pathways.
In 2005, Dr. Hui started his post-doctoral training at The Children Hospital of Philadelphia under Dr. Katherine High, M.D., studying the adaptive immune response to adeno-associated virus (AAV) used in gene therapy. In 2014, Daniel transitioned to industry as the lab group formed Spark Therapeutics, which in 2017 successfully launched the first FDA-approved AAV gene therapy product in the U.S. In 2019, Dr. Hui joined Tmunity Therapeutics and began a new journey with T cell-based therapies to fight cancer.